Agilon Health, Inc.
NYSE:AGLMedical - Care Facilities
+$2.26 today
- Market cap
- $1.52B
- Beta
- 3.04
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$22.50
Volume 0.79M
Average 0.41M
AGL Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Agilon Health, Inc.NYSE: AGL
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns positive
Q1 FY2026 free cash flow was $20.63M, compared with -$42.87M a year earlier. Trailing-twelve-month free cash flow was -$76.61M. Over 3 fiscal years it compounded at -10.0% a year.
Context
- Free cash flow amounted to 2.0% of revenue in FY2025, up 0.8 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly free cash flow holds near $20.63M or moves back toward the trailing-twelve-month quarterly average of -$19.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (119.01M) USD
- Year-over-year change
- -67.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (119.01M) | -67.5% |
| FY2024 | 2024-12-31 | (71.03M) | +62.0% |
| FY2023 | 2023-12-31 | (187.01M) | -14.4% |
| FY2022 | 2022-12-31 | (163.47M) | -1.2% |
| FY2021 | 2021-12-31 | (161.59M) | — |
Free Cash Flow vs competitors
How AGL compares with its peers on the latest reported figures
- AGL's LTM Mar 2026 free cash flow of $76.61M is the 5th largest of the 10 companies compared; the peer median is $45.99M.
- Its year-over-year change of +26.2% is the 8th highest of 10, against a peer median of +50.2%.
- Free cash flow amounts to 1.3% of revenue for AGL, versus a peer median of 28.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $183.16M | +30.9% | +14.9% | — | |
| LTM Mar 2026 | $151.54M | +67.5% | +29.0% | — | |
| LTM Mar 2026 | $131.32M | +50.2% | +60.0% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $111.39M | +46.6% | +78.4% | — |
| LTM Mar 2026 | $76.61M | +26.2% | -10.0% | 1.3% | |
| LTM Mar 2026 | $45.99M | +1079.1% | +272.9% | 1173.4% | |
| LTM Mar 2026 | $45.43M | -2.6% | -21.7% | 56.0% | |
| LTM Mar 2026 | $37.06M | -22.6% | +10.8% | 15.6% | |
| LTM Feb 2026 | $22.87M | +130.8% | +7.7% | 28.4% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $138.36K | +63.1% | — | 2.2% |
| Peer median (excluding AGL) | $45.99M | +50.2% | +22.0% | 28.4% | |
Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (406.79M) | (106.86M) | (262.8M) | (260.1M) | (391.35M) |
| Depreciation & Amortization | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M |
| Deferred Income Tax | (3.23M) | 532K | 0 | 0 | 0 |
| Stock-Based Compensation | 292.39M | 28.38M | 69.33M | 50.66M | 49.12M |
| Change in Working Capital | (55.03M) | (59.44M) | (10.07M) | 130.59M | 189.47M |
| Accounts Receivables | (149.04M) | (204.17M) | 0 | (74.58M) | 344.59M |
| Inventory | 149.04M | 0 | 0 | 0 | 0 |
| Accounts Payables | 95.7M | 173.45M | 473.61M | 198.58M | (87.48M) |
| Other Working Capital | (150.72M) | (28.72M) | (483.68M) | 6.59M | (67.64M) |
| Other Non-Cash Items | 9.82M | (7.19M) | 27.18M | (3.39M) | 18.4M |
| Operating Cash Flow | (148.16M) | (130.81M) | (156.2M) | (57.78M) | (105.76M) |
| Capital Expenditures | (13.43M) | (32.66M) | (30.82M) | (13.25M) | (13.24M) |
| Acquisitions (Net) | (1.34M) | 500K | (43.06M) | 0 | 0 |
| Purchases of Investments | (7.1M) | (458.27M) | (114.66M) | (12.01M) | (60.15M) |
| Sales of Investments | 7.1M | 52.55M | 164.04M | 206.92M | 193.87M |
| Other Investing Activities | (75.74M) | (23.75M) | (34.51M) | (41.77M) | (31.87M) |
| Investing Cash Flow | (90.51M) | (444.39M) | (44.02M) | 139.89M | 88.61M |
| Debt Repayment | (19.9M) | (5M) | (5M) | (3.75M) | 0 |
| Common Stock Issued | 1.19B | 33.06M | 11.87M | 1.17M | 0 |
| Common Stock Repurchased | 0 | 0 | (200M) | 0 | (2.99M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.74M) | 0 | 11.87M | 0 | 0 |
| Financing Cash Flow | 1.15B | 28.06M | (193.13M) | (2.58M) | (2.99M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 915.73M | (547.14M) | (393.35M) | 79.53M | (20.15M) |
| Free Cash Flow | (161.59M) | (163.47M) | (187.01M) | (71.03M) | (119.01M) |
Agilon Health, Inc.
NYSE:AGL
Intrinsic Alpha fair value
Locked
Current Price
$90.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.